Practice
Featured experience
Bristol Myers Squibb €5 billion notes offering
We advised the underwriters on Bristol Myers Squibb Ireland’s inaugural euro issuance
BETA Technologies $1 billion IPO
The shares are listed on the New York Stock Exchange
Vistra $2 billion secured notes offering
The investment-grade notes are due 2028, 2030 and 2035
American Industrial Partners $1.5 billion acquisition of Global Cellulose Fibers
We are advising American Industrial Partners on the transaction
Weyerhaeuser $750 million bond offering
Davis Polk advised the joint book-running managers, in connection with an SEC-registered offering by Weyerhaeuser…
General Dynamics $4 billion notes offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in an SEC-registered…
Textron $650 million notes offering
Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering by…
Enphase Energy $320 million convertible notes offering
Davis Polk advised the joint book-running managers in connection with a Rule 144A offering by Enphase Energy, Inc. of $320…
Honeywell International €1 billion notes offering
Davis Polk advised the joint book-running managers in connection with an SEC-registered offering by Honeywell…
J. M. Smucker $800 million notes offering
Davis Polk advised several underwriters in connection with an SEC-registered offering of $500 million aggregate principal…
Canadian Pacific Railway $500 million notes offering
Davis Polk advised the joint book-running managers in connection with the offering by Canadian Pacific Railway Company…
Freeport-McMoRan $1.3 billion notes offering
Davis Polk advised Freeport-McMoRan Inc. (“FCX”) in connection with its SEC-registered offering of $1.3 billion of senior…
W.W. Grainger $500 million notes offering
Davis Polk advised the underwriters on an SEC-registered offering by W.W. Grainger of $500 million aggregate principal…
BioXcel Therapeutics $73.6 million stock offering
Davis Polk advised the underwriters in connection with the SEC-registered offering by BioXcel Therapeutics, Inc. of 2,300…